GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (BUE:LLY) » Definitions » Cyclically Adjusted PS Ratio

Eli Lilly and Co (BUE:LLY) Cyclically Adjusted PS Ratio : 30.93 (As of Jun. 12, 2024)


View and export this data going back to . Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PS Ratio?

As of today (2024-06-12), Eli Lilly and Co's current share price is ARS17837.50. Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ARS576.68. Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is 30.93.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

BUE:LLY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.48   Med: 5.01   Max: 29.07
Current: 29.07

During the past years, Eli Lilly and Co's highest Cyclically Adjusted PS Ratio was 29.07. The lowest was 2.48. And the median was 5.01.

BUE:LLY's Cyclically Adjusted PS Ratio is ranked worse than
98.52% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs BUE:LLY: 29.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Eli Lilly and Co's adjusted revenue per share data for the three months ended in Mar. 2024 was ARS32,693.251. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ARS576.68 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PS Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.92 7.43 11.14 13.57 20.20

Eli Lilly and Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.48 16.73 18.76 20.20 26.12

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PS Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Eli Lilly and Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=17837.50/576.68
=30.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Eli Lilly and Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=32693.251/131.7762*131.7762
=32,693.251

Current CPI (Mar. 2024) = 131.7762.

Eli Lilly and Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 149.022 100.560 195.283
201409 152.821 100.428 200.524
201412 163.703 99.070 217.747
201503 153.570 99.621 203.138
201506 169.816 100.684 222.257
201509 175.113 100.392 229.857
201512 261.349 99.792 345.112
201603 267.331 100.470 350.629
201606 285.096 101.688 369.452
201609 292.018 101.861 377.780
201612 343.302 101.863 444.118
201703 305.234 102.862 391.034
201706 363.376 103.349 463.326
201709 375.560 104.136 475.244
201712 238.809 104.011 302.558
201803 381.084 105.290 476.950
201806 540.827 106.317 670.337
201809 761.137 106.507 941.722
201812 832.556 105.998 1,035.031
201903 809.163 107.251 994.200
201906 1,089.518 108.070 1,328.520
201909 1,333.846 108.329 1,622.543
201912 1,596.686 108.420 1,940.648
202003 1,595.760 108.902 1,930.949
202006 1,653.261 108.767 2,002.996
202009 1,870.450 109.815 2,244.511
202012 2,648.820 109.897 3,176.175
202103 2,687.630 111.754 3,169.143
202106 2,805.315 114.631 3,224.891
202109 2,908.407 115.734 3,311.541
202112 3,490.826 117.630 3,910.650
202203 3,700.687 121.301 4,020.268
202206 3,458.638 125.017 3,645.639
202209 4,268.800 125.227 4,492.070
202212 5,410.737 125.222 5,693.948
202303 6,088.555 127.348 6,300.279
202306 8,839.721 128.729 9,048.991
202309 14,776.773 129.860 14,994.875
202312 14,943.319 129.419 15,215.445
202403 32,693.251 131.776 32,693.251

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (BUE:LLY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Eli Lilly and Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (BUE:LLY) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (BUE:LLY) Headlines

From GuruFocus

Q1 2023 Eli Lilly and Co Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Eli Lilly and Co Earnings Call Transcript

By GuruFocus Research 01-23-2024

Eli Lilly and Co at Citi BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Eli Lilly and Co Earnings Call Transcript

By GuruFocus Research 01-23-2024

Eli Lilly and Co Guidance Call 2023 Transcript

By GuruFocus Research 01-23-2024